Ongoing advances in quantitative PpIX fluorescence guided intracranial tumor resection (Conference Presentation)

2016 ◽  
Author(s):  
Jonathan D. Olson ◽  
Stephen C. Kanick ◽  
Jaime J. Bravo ◽  
David W. Roberts ◽  
Keith D. Paulsen
Keyword(s):  
Tumor Resection ◽  
Intracranial Tumor

scholarly journals P3-308: PREOPERATIVE FACTORS ASSOCIATED WITH POSTOPERATIVE DELIRIUM AFTER INTRACRANIAL TUMOR RESECTION

2019 ◽  
Vol 15 ◽  
pp. P1055-P1056
Author(s):  
Carmen Ojeda-lopez ◽  
Guillermo Peñaloza-Solano ◽  
Regina Rodriguez-Arias ◽  
Jesús Ramírez-Bermúdez
Keyword(s):  
Postoperative Delirium ◽  
Tumor Resection ◽  
Intracranial Tumor ◽  
Factors Associated ◽  
Preoperative Factors

Metabolic Syndrome Associated with Increased Rates of Medical Complications After Intracranial Tumor Resection

2019 ◽  
Vol 126 ◽  
pp. e1055-e1062 ◽  
Author(s):  
Anna M. Nia ◽  
Daniel W. Branch ◽  
Ken Maynard ◽  
Thomas Frank ◽  
Dmitry Zavlin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Tumor Resection ◽  
Intracranial Tumor ◽  
Medical Complications

scholarly journals Anesthetic Management for Cesarean Delivery in a Patient with a Gigantic Intracranial Tumor

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
C. dos Santos e Santos ◽  
C. L. Mason ◽  
J. S. Neill ◽  
B. E. Grayson ◽  
A. Calimaran ◽  
...  
Keyword(s):  
Cesarean Delivery ◽  
Anesthetic Management ◽  
Tumor Resection ◽  
Intracranial Tumor ◽  
Transversus Abdominis ◽  
Surgical Team ◽  
Transversus Abdominis Plane ◽  
Postoperative Pain Control ◽  
Brain Tumor Resection ◽  
Endotracheal Anesthesia

A 31-year-old G5P1 patient with unremarkable past medical history at 29 weeks of gestation was diagnosed with a gigantic left frontotemporal brain mass. Initial clinical management as an inpatient achieved an improvement in the symptoms. The patient and surgical team agreed to schedule a cesarean delivery at 32 weeks of gestation if no neurological deterioration was observed. Intraoperative course with general endotracheal anesthesia and bilateral transversus abdominis plane block was uneventful and promoted efficient postoperative pain control. Seven days after delivery, the patient underwent craniotomy for brain tumor resection. This report describes the anesthetic management of a patient with an intracranial tumor during pregnancy.

A Predictive Model of Unfavorable Outcomes After Benign Intracranial Tumor Resection

2015 ◽  
Vol 84 (1) ◽  
pp. 82-89 ◽  
Author(s):  
Kimon Bekelis ◽  
Piyush Kalakoti ◽  
Anil Nanda ◽  
Symeon Missios
Keyword(s):  
Predictive Model ◽  
Tumor Resection ◽  
Intracranial Tumor

scholarly journals Efficacy of a topical gelatin-thrombin hemostatic matrix, FLOSEAL®, in intracranial tumor resection

2020 ◽  
Vol 11 ◽  
pp. 16
Author(s):  
Dai Kamamoto ◽  
Tokunori Kanazawa ◽  
Eriko Ishihara ◽  
Kaoru Yanagisawa ◽  
Hideyuki Tomita ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Adverse Events ◽  
Postoperative Bleeding ◽  
Tumor Resection ◽  
Intracranial Tumor ◽  
Hemostatic Agent ◽  
Life Threatening ◽  
Hospital Stays ◽  
Brain Tumor Resection ◽  
Rate Of Success

Background: Hemostasis plays an important role in safe brain tumor resection and also reduces the risk for surgical complications. This study aimed to evaluate the efficacy of FLOSEAL®, a topical hemostatic agent that contains thrombin and gelatin granules, in brain tumor resections. Methods: We evaluated the hemostatic effect of FLOSEAL by scoring the intensity of bleeding from 1 (mild) to 4 (life threatening). We assessed the rate of success of hemostasis with 100 patients who underwent intracranial tumor resection. We also investigated the duration of the operation, the amount of intra- and postoperative bleeding, the number of hospital stays, and adverse events in patients who used FLOSEAL compared with those who did not use FLOSEAL. Results: FLOSEAL was applied to a total of 109 bleeding areas in 100 patients. A total of 95 bleeding areas had a score of 1 and 91 (96%) showed successful hemostasis. Thirteen bleeding areas scored 2 and 8 (62%) showed hemostasis with the first application of FLOSEAL. The second application was attempted with five bleeding areas and four showed hemostasis. About 94% (103/109 areas) of bleeding points successfully achieved hemostasis by FLOSEAL. Moreover, FLOSEAL significantly decreased the amount of intraoperative bleeding and postoperative bleeding as assessed with computed tomography on 1 day postoperatively compared with no use of FLOSEAL. There were no adverse events related to FLOSEAL use. Conclusion: Our results indicate that FLOSEAL is a reliable, convenient, and safe topical hemostatic agent for intracranial tumor resection.

Sign in / Sign up

Export Citation Format

Share Document